These data were confirmed after blocking TNFα with infliximab in a mouse model of ovarian cancer and were also consistent with clinical results; patients with advanced ovarian cancer treated with infliximab exhibited substantially reduced plasma and ascitic levels of IL-17. Here, IL17A is linked to ovarian cancer.